Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial
ConclusionIn patients with MCI, a 32-week trial with slow-release exenatide had no beneficial effect on cognitive performance.Trial registration numberNCT03881371, registered on 21 July, 2016. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - April 2, 2024 Category: Endocrinology Source Type: research
Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
CONCLUSION: This study evaluated the efficacy of GLP-1RAs in patients with NAFLD and NASH. These results suggest that GLP-1RAs may be a potential and viable therapeutic approach as a targeted agent to intervene in disease progression of NAFLD and NASH.PMID:38555202 | DOI:10.1016/j.pcd.2024.03.005 (Source: Primary Care)
Source: Primary Care - March 30, 2024 Category: Primary Care Authors: Lixuan Fang Jine Li Haixia Zeng Jianping Liu Source Type: research
Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
CONCLUSION: This study evaluated the efficacy of GLP-1RAs in patients with NAFLD and NASH. These results suggest that GLP-1RAs may be a potential and viable therapeutic approach as a targeted agent to intervene in disease progression of NAFLD and NASH.PMID:38555202 | DOI:10.1016/j.pcd.2024.03.005 (Source: Primary Care)
Source: Primary Care - March 30, 2024 Category: Primary Care Authors: Lixuan Fang Jine Li Haixia Zeng Jianping Liu Source Type: research
Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis
CONCLUSIONS: Treatment with GLP-1 RA and SGLT2i can lower IMT in diabetic patients, and GLP-1 RA may be more effective than SGLT2i.PMID:38529046 | PMC:PMC10963118 | DOI:10.1155/2024/3212795 (Source: Cell Research)
Source: Cell Research - March 26, 2024 Category: Cytology Authors: Abolfazl Akbari Shiva Hadizadeh Leida Heidary Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study
ConclusionsThis study provided real-world evidence showing that GLP-1RA significantly improved HbA1c, body weight, and SBP. The results can inform the decision-making about GLP-1RA treatment in daily clinical practice. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - March 8, 2024 Category: Endocrinology Source Type: research
Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial
CONCLUSION: Combined with intensive lifestyle interventions, a 26-week treatment with exenatide was not demonstrated superior to placebo to treat craniopharyngioma-related obesity.PMID:38450721 | DOI:10.1093/ejendo/lvae024 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 7, 2024 Category: Endocrinology Authors: Blandine Gatta-Cherifi Kamel Mohammedi Tanguy Cariou Christine Poitou Philippe Touraine Gerald Raverot Thierry Brue Philippe Chanson Fr édéric Illouz Solange Grunenwald Olivier Chabre Emmanuel Sonnet Thomas Cuny Jer ôme Bertherat S ébastien Czernichow Source Type: research
Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial
CONCLUSION: Combined with intensive lifestyle interventions, a 26-week treatment with exenatide was not demonstrated superior to placebo to treat craniopharyngioma-related obesity.PMID:38450721 | DOI:10.1093/ejendo/lvae024 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 7, 2024 Category: Endocrinology Authors: Blandine Gatta-Cherifi Kamel Mohammedi Tanguy Cariou Christine Poitou Philippe Touraine Gerald Raverot Thierry Brue Philippe Chanson Fr édéric Illouz Solange Grunenwald Olivier Chabre Emmanuel Sonnet Thomas Cuny Jer ôme Bertherat S ébastien Czernichow Source Type: research
